Yunkang Group Ltd (2325) Fair Value & Analysis
Healthcare · HK · Market cap HK$398M
Fair value as of: Aug 13, 2026
From 23 valuation models · updated 3 days ago
Share price +8.3% over the past month.
A solid business, but screening 74% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (HK$0.1900). The favourable scenario is already priced in.
- Solid but not exceptional quality (66/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (4 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
51‑month range HK$0.5900 – HK$18.62 · fair‑value band HK$0.1600 – HK$0.1900 · the HK$0.6500 price screens above the HK$0.1700 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Yunkang Group Ltd (2325) currently trades at HK$0.6500, while our model-based Fair Value estimate is HK$0.1700, implying the stock looks roughly 73.9% overvalued today. The Quality Score stands at 66/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Yunkang Group Ltd generated revenue of HK$601M at a net margin of 0.5%. Revenue declined 13.2% year over year. It earns a return on equity of 0.3%. The balance sheet holds a net cash position of HK$894M. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$0.1600 (bear case) to HK$0.1900 (bull case); at HK$0.6500, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -50% fair-value upside, at -74%, 2325 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 23 models by family
Widest divergence: DCF Models (HK$5.15) versus Earnings-Based (HK$0.0400). Highest evidence: Growth DCF (80).
Notify me when 2325 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 63 · Market factors (momentum, volatility) 22
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Yunkang Group Limited operates as a medical operation service provider in the People's Republic of China. The company offers diagnostic testing services for medical institution alliances, including setting up or upgrading diagnostic centers, the establishment of standard operating procedures for diagnostic testing, diagnostic consultation and staff …
Full company description
Yunkang Group Limited operates as a medical operation service provider in the People's Republic of China. The company offers diagnostic testing services for medical institution alliances, including setting up or upgrading diagnostic centers, the establishment of standard operating procedures for diagnostic testing, diagnostic consultation and staff training, procurement of equipment, smart internet of things, and logistics assistance. It also provides diagnostic outsourcing services comprising pathology tests; infectious disease diagnostic tests; and genetic reproduction and screening tests. In addition, the company offers routine diagnostic tests for chronic kidney, blood, autoimmune, endocrine metabolism, and other diseases. Further, it provides technology platforms, including AI + healthcare; high-throughput sequencing technology platform; PCR technology platform; digital pathology remote diagnosis platform; and other technology platforms. The company provides its services through independent clinical laboratories and on-site diagnostic centers. Yunkang Group Limited was founded in 2008 and is headquartered in Guangzhou, the People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Yunkang Group Ltd reported revenue of HK$601M in FY2025 versus HK$1.7B in FY2021, a compound −22.8%/yr. Reported net income was HK$2.9M in FY2025, compounding −70.4%/yr from FY2021.
2325 screens 74% overvalued. Compare with Thermo Fisher Scientific Inc →
Peer Group
Diagnostics & Research · 136 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $603.01 | $308.19 | -49% |
| Danaher Corporation DHR | $205.79 | $103.88 | -50% |
| WuXi AppTec Co 2359 | HK$198.90 | HK$157.39 | -21% |
| Lonza Group LONN | CHF 566.20 | CHF 259.80 | -54% |
| IDEXX Laboratories, Inc IDXX | $570.58 | $255.77 | -55% |
| Agilent Technologies, Inc A | $148.24 | $61.53 | -58% |
| Waters Corporation WAT | $416.15 | $121.96 | -71% |
| IQVIA Holdings IQV | $243.84 | $132.17 | -46% |
| Illumina, Inc ILMN | $192.91 | $95.51 | -50% |
| Mettler-Toledo International Inc MTD | $1,437 | $615.78 | -57% |
Compare Yunkang Group Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Yunkang Group Ltd (2325) overvalued or undervalued?
What is the fair value of 2325?
What is the quality score of 2325?
What is the revenue of Yunkang Group Ltd (2325)?
What is the net profit margin of 2325?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Yunkang Group Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.